Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era

OBJECTIVE: First-line therapy for metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) has been revolutionized by the introduction of anti-checkpoint monoclonal antibodies, which have shown a significant improvement in overall survival (OS) gaining approval in a first line setting. Ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Botticelli, Andrea, Pomati, Giulia, Cirillo, Alessio, Mammone, Giulia, Ciurluini, Fabio, Cerbelli, Bruna, Sciattella, Paolo, Ralli, Massimo, Romeo, Umberto, De Felice, Francesca, Catalano, Carlo, Vullo, Francesco, Della Monaca, Marco, Amirhassankhani, Sasan, Tomao, Silverio, Valentini, Valentino, De Vincentiis, Marco, Tombolini, Vincenzo, Della Rocca, Carlo, Polimeni, Antonella, di Gioia, Cira, Corsi, Alessandro, D’Amati, Giulia, Mezi, Silvia, Marchetti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274020/
https://www.ncbi.nlm.nih.gov/pubmed/34253248
http://dx.doi.org/10.1186/s12967-021-02975-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274020/
https://www.ncbi.nlm.nih.gov/pubmed/34253248
http://dx.doi.org/10.1186/s12967-021-02975-3

Ejemplares similares